Year: 2020

BERGENBIO HOSTING VIRTUAL R&D Day TODAY

November 13, 2020

Bergen, Norway, 06 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT annual SITC meeting

November 11, 2020

Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO TO PRESENT AT Sachs Annual Biotech in Europe Forum

September 18, 2020

Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

September 1, 2020

Bergen, Norway, 01 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020

August 18, 2020

Bergen, Norway, 18 August 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

August 10, 2020

Bergen, Norway, 10 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More